GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Piotroski F-Score

Renalytix (Renalytix) Piotroski F-Score : 2 (As of May. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Renalytix Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Renalytix has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Renalytix's Piotroski F-Score or its related term are showing as below:

RNLX' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 6
Current: 2

During the past 6 years, the highest Piotroski F-Score of Renalytix was 6. The lowest was 1. And the median was 2.


Renalytix Piotroski F-Score Historical Data

The historical data trend for Renalytix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Piotroski F-Score Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 6.00 1.00 2.00

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 2.00 2.00

Competitive Comparison of Renalytix's Piotroski F-Score

For the Health Information Services subindustry, Renalytix's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Piotroski F-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Renalytix's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -11.104 + -10.154 + -9.132 + -7.743 = $-38.13 Mil.
Cash Flow from Operations was -8.633 + -9.504 + -7.843 + -4.938 = $-30.92 Mil.
Revenue was 0.518 + 0.459 + 0.709 + 0.535 = $2.22 Mil.
Gross Profit was -0.155 + -0.043 + 0.257 + -0.066 = $-0.01 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(39.802 + 30.629 + 19.54 + 21.874 + 8.769) / 5 = $24.1228 Mil.
Total Assets at the begining of this year (Mar23) was $39.80 Mil.
Long-Term Debt & Capital Lease Obligation was $4.89 Mil.
Total Current Assets was $6.34 Mil.
Total Current Liabilities was $14.99 Mil.
Net Income was -5.153 + -11.953 + -10.444 + -12.106 = $-39.66 Mil.

Revenue was 0.831 + 0.969 + 1.192 + 0.724 = $3.72 Mil.
Gross Profit was 0.139 + 0.273 + 0.481 + 0.121 = $1.01 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(44.466 + 50.065 + 38.713 + 30.66 + 39.802) / 5 = $40.7412 Mil.
Total Assets at the begining of last year (Mar22) was $44.47 Mil.
Long-Term Debt & Capital Lease Obligation was $7.02 Mil.
Total Current Assets was $35.73 Mil.
Total Current Liabilities was $14.68 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Renalytix's current Net Income (TTM) was -38.13. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Renalytix's current Cash Flow from Operations (TTM) was -30.92. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-38.133/39.802
=-0.95806743

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-39.656/44.466
=-0.89182746

Renalytix's return on assets of this year was -0.95806743. Renalytix's return on assets of last year was -0.89182746. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Renalytix's current Net Income (TTM) was -38.13. Renalytix's current Cash Flow from Operations (TTM) was -30.92. ==> -30.92 > -38.13 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=4.892/24.1228
=0.2027957

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=7.021/40.7412
=0.17233169

Renalytix's gearing of this year was 0.2027957. Renalytix's gearing of last year was 0.17233169. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=6.34/14.988
=0.42300507

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=35.728/14.684
=2.43312449

Renalytix's current ratio of this year was 0.42300507. Renalytix's current ratio of last year was 2.43312449. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Renalytix's number of shares in issue this year was 48.827. Renalytix's number of shares in issue last year was 42.78. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.007/2.221
=-0.00315173

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.014/3.716
=0.27287406

Renalytix's gross margin of this year was -0.00315173. Renalytix's gross margin of last year was 0.27287406. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=2.221/39.802
=0.05580122

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=3.716/44.466
=0.08356947

Renalytix's asset turnover of this year was 0.05580122. Renalytix's asset turnover of last year was 0.08356947. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Renalytix has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Renalytix  (NAS:RNLX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Renalytix Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Renalytix's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Executives
Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Renalytix (Renalytix) Headlines

From GuruFocus